In preclinical and early phase clinical studies, it appears that it is possible to down regulate Src activity. In a preclinical model using mouse xenografts and the Src inhibitor saracatinib (AZD0530), Src activity was measured by phosphorylation levels of the target proteins FAK (p-FAK) and pax (p-pax); and, as a corollary, Src inhibition induced by saracatinib was measured by decreased phosphorylation of these proteins (7). A recent phase I trial of saracatinib utilized this biomarker platform in 81 patients with advanced solid tumors, including 13 with metastatic breast cancer, and demonstrated a reduction in tumor Src activity function and physiologic bone resorption with deletion of the c-src gene resulting in osteopetrosis (10) . In an animal model using human breast cancer cell lines, Src activity was associated with osteolytic bone metastases likely through regulation of both cell growth and production of parathyroid hormone-related protein (11). Given Src's role in lytic metastasis to bone, markers of bone resorption, such as urinary cross-linked N-telopeptide of type I collagen (NTX), may also serve as important biomarkers of Src activity.
Dasatinib, an FDA-approved therapy for chronic myelogenous leukemia and Philadelphia (Ph+) acute lymphoblastic leukemia, is a potent orally-available inhibitor of multiple oncogenic tyrosine kinases including Src family kinases (SFKs), the fusion protein Bcr-Abl, c-Kit, and platelet-derived growth factor receptor (PDGFR) (12) (13) . In the phase I setting investigating the use of dasatinib in advanced solid tumors, dasatinib demonstrated a generally tolerable safety profile, with a dose-limiting toxicity of pleural effusions, as well as preliminary evidence of efficacy (14) (15) .
In order to optimize drug efficacy and patient selection for targeted agents such as dasatinib there is a need for adaptive trial methodologies and validated biomarker endpoints. To further investigate dasatinib as a potential treatment for advanced breast cancer, we conducted a phase II study with paired metastatic tumor biopsies wherein real-time assessment of potential tissue biomarkers of
Study Design and Drug Administration
This was a 2-stage phase II single-arm multi-site study of dasatinib given as monotherapy for metastatic breast cancer. The total planned accrual was 60 patients with a planned interim analysis of progression in the first 31 patients (stage 1). Each treatment cycle of dasatinib was 28 days. Metastatic site biopsies were conducted at baseline and at the conclusion of cycle 1 (week 4). These tissue biopsies were analyzed using quantitative immunohistochemistry (IHC), measured in optical densitometry (OD) units, for the following tissue biomarkers: p-FAK, p-pax, and p-Src. These procedures are described in detail below under "Tissue Biomarker Analysis."
For the purposes of these analyses we defined optimal evidence of Src inhibition by biomarker analysis was predefined as ≥80% inhibition of phosphorylation of both FAK and pax at the week 4 biopsy compared to the phosphorylation levels of these proteins from the baseline biopsy for the same patient. Accordingly, suboptimal evidence of Src inhibition by biomarker analysis was defined as <80% inhibition of phosphorylation of either FAK or pax compared to baseline phosphorylation levels.
Within the first 31 patients there were two pre-planned treatment groups: group A (the first 15 patients) and group B (the subsequent 16 patients). The starting dose of dasatinib for group A was 50 mg orally twice daily. In the study design, an escalation of the starting dose for group B to 70 mg orally twice daily was planned if less than 10 patients in group A had week 4 biopsies that showed ≥ 80% inhibition of both p-FAK and p-paxillin. The purpose of this planned weeks after dasatinib administration due to the risk of hypocalcemia.
Patients were required to have normal heart function with left ventricular ejection fraction (LVEF) ≥ 50% and normal electrocardiogram. Eligibility required normal bone marrow and organ function as documented by the following parameters: granulcytes ≥ 1,500/µL; platelets ≥ 100,000/µL; hemoglobin ≥ 9 gm/dL; total bilirubin < 2 x upper limit of normal (ULN); AST, ALT, and alkaline phosphatase ≤ 2.5 x ULN; serum creatinine ≤ 3 x ULN. Serum sodium, potassium, magnesium, phosphate and calcium were all required to be ≥ lower This study was approved by the Duke institutional review board as well as the local institutional review boards for all participating sites through the Duke Breast Cancer Working Group. Informed and written consent was obtained from all study patients prior to any study-related tests or treatments.
Study Evaluations
The pre-study evaluation, conducted within 14 days of registration, 
Tissue Biomarker Analysis
Site selection for the metastatic biopsies, including imaging as appropriate, was determined on a patient-by-patient basis by the treating physician. The least invasive site for biopsy was preferred in order to prioritize patient safety and minimize the risk for biopsy-related complications. The goal for tissue collection was at least 100 mcg of tumor-containing tissue, to be collected either via core needle biopsy or punch biopsy. For each patient, the same metastatic site was biopsied at baseline and week 4. For the week 4 biopsy, patients were instructed to hold the morning dose of dasatinib until 1 hour before biopsy procedure. Richmond, IL). Slides were scored by a board certified pathologist using a 1 score system (0, 1+, 2+, 3+). Image analysis was performed using an Aperio ScanScope XT using a positive pixel count algorithm to measure amount of staining and reported in optical density (OD) units (17) .
Statistical Methods
The primary objectives of this study were to assess the 16-week progression-free rate and the tolerability of single agent dasatinib. Progressionfree survival (PFS) was defined as the time from the start of treatment to disease progression or death due to any cause; patients who went off-treatment due to toxicity or voluntary withdrawal were censored. A two-stage "admissible" design was used to test the null hypothesis that the 16-week progression-free rate was ≤ 0.12 against the alternative hypothesis that the progression-free rate was ≥ 0.25 (18) . At least 4 of the first 31 patients were required to be progression-free at 16 weeks in order for a second stage of 29 patients to be enrolled. At least 11 of the 
60 patients had to be progression-free in order to reject the null. This design has a Type I error rate of 0.09 and a power of 0.90. PFS was described with a Kaplan-Meier plot. All toxicities were tabulated by type and grade. Of primary interest were the proportion of patients who developed pleural effusions and the proportion of patients who suffered any toxicities of grade 3 or higher. Relative change in biomarker level from baseline to week 4 was calculated as the change divided by the baseline value; relative change was described by calculating the median and range.
RESULTS

Patient Characteristics
The trial stopped accrual early in that none of the patients from the first Patients received a median of 2 prior lines of chemotherapy for MBC (range, 0 to 7). Twenty-four patients (78%) had previously been treated with an anthracycline; of these, 14 (45%) had been treated in the (neo)adjuvant setting only, 7 (23%) in the metastatic setting only, and 3 (10%) in both settings. Twentyseven patients (86%) had previously been treated with a taxane; of these, 2 (6%) had been treated in the (neo)adjuvant setting only, 11 (35%) in the metastatic setting only, and 14 (45%) in both settings.
Safety
Toxicity data are available for all 31 patients. Table 2 gives the frequencies of all toxicities with incidence of >10% by grade, regardless of attribution; grade 3 toxicities, regardless of incidence or attribution are also included. The most common toxicities, with frequencies, were nausea (61% of patients), pleural effusions (52%), fatigue (52%), rash (52%), diarrhea (48%), and anorexia (42%). For each of these common toxicities, the majority were grades 1 and 2. Grade 3 toxicities were as follows: pain (12%), anorexia (10%), dyspnea (10%), pleural effusions (10%), pneumonitis (6%), elevated AST (6%), and DVT (6%). In addition, each of the following grade 3 toxicities was reported by 1 patient: fatigue, nausea, hyponatremia, thrombocytopenia, and cellulitis. There 
Correlative Science
All 31 patients had a baseline biopsy; 25 of these patients also had metastatic biopsy at week 4. Of these 25 patients, 20 of the paired metastatic biopsies were evaluable and 5 were not due to insufficient tissue quality. Of the other 6 patients, a week 4 biopsy was not performed for the following reasons: 1 patient experienced disease progression prior to 4 weeks, 2 were removed from protocol therapy due to toxicity, and 3 patients voluntarily withdrew. The biopsy sites were as follows: liver (10 patients, 32%), lymph node (9 patients, 29%), chest wall and other soft tissue nodules (12 patients, 39%). Twenty-two patients had urinary samples at baseline and week 4 that were evaluable for serial urinary NTX levels; the median change in urinary NTX levels during this time range was -19% (range, -62% to +60%). Although only 7 patients had urinary samples at week 4 and week 8 that were evaluable for urinary NTX levels, the median change in urinary NTX levels from week 4 to week 8 was comparable at -18% (range, -56% to +50%).
DISCUSSION
In this study, the lack of significant anti-tumor activity of dasatinib could be attributed to many factors, including the use of dasatinib as a single-agent, the number of prior therapies allowed, characteristics of our patient population or their breast cancer tumor characteristics, the small study size, and drug toxicities limiting the length of dasatinib exposure. These results are in contrast to two 
recent phase II studies that also evaluated single-agent dasatinib for advanced breast cancer (19, 20) . In the first study, Finn and colleagues treated 44 patients with triple-negative MBC, 66% of whom had received prior therapy for advanced disease, and demonstrated a clinical benefit rate (defined as partial response or stable disease lasting at least 16 weeks) of 9.3% (19). In the second study, Mayer and colleagues treated 68 patients with HER2-amplified and/or hormone receptor (HR)-positive MBC, 93% of whom had received prior therapy for metastases, and demonstrated a clinical benefit rate of 19%; interestingly, all patients who achieved some degree of disease control were HR-positive (20) .
Both studies demonstrated that tolerability of dasatinib was better when the dose was reduced from 100 mg twice daily to 70 mg twice daily. Thus, other studies have shown modest clinical benefit for use of single-agent dasatinib in women with metastatic breast cancer. In the current study, however, patients were eligible regardless of HER2 or HR status and no patients met the primary study endpoint of progression-free survival at 16 weeks.
Major limitations of this study were drug inefficacy and toxicity. Due to these limitations the median time on study of only 44 days, less than 2 cycles of dasatinib therapy. The majority of patients experienced disease progression prior to 16 weeks (52%) with toxicity (26%) being the second most common reason for study discontinuation. These results are comparable to those reported in a recent phase II trial of sorafenib, an orally-available tyrosine kinase inhibitor which also has multiple targets including vascular endothelial growth factor receptors, PDGFR, and c-Kit, which was stopped after the first cohort of 23 patients due to lack of efficacy; patients received treatment for a median of two 28-day cycles and no patients experienced a partial or complete response to therapy (21) .
In this study, the correlative science was focused on dasatinib's mechanism as a Src inhibitor and there were no clinically meaningful changes in the tissue levels of p-FAK, p-pax, and p-Src from baseline biopsy to week 4 biopsy. Regarding tissue quality, 25 patients underwent paired metastatic biopsies; 5 of these paired samples were not evaluable due to insufficient tissue quality. Of these 5 inevaluable pairs, 2 were ultrasound-guided liver biopsies and 3 were punch biopsies of chest wall and other soft tissue nodules. Recalling that of the 25 patients who underwent paired metastatic biopsies, 10 patients had paired ultrasound-guided liver biopsies and 12 patients had paired punch biopsies of the chest wall and other soft tissue nodules, the failure rate of these two sites and methods is comparable at 20% and 25% respectively. While these are small numbers, our results do not suggest that either site (liver or soft tissue nodules) or method (ultrasound-guided biopsy or punch biopsy) influenced the success rate for acquisition of tissue of sufficient quality for biomarker analysis.
For multi-targeted tyrosine kinase inhibitors such as dasatinib, establishing appropriate tissue biomarker endpoints is challenging in that the drug may affect multiple targets of more or less clinical relevance and the dose levels and length of exposure required to achieve significant biomarker change may be undefined.
We are seeking to establish biomarkers of dasatinib activity through additional correlative investigation including full genomic analyses. by multiple factors such as tumor heterogeneity and the potential for discordance between the primary and metastatic sites (24) .
To address these and other concerns, Pintilie and colleagues have identified two major sources of error in tissue biomarker studies, inherent tumor heterogeneity and technical difficulties with the assay, and they have proposed methods to minimize each of these errors (25) . Error due to tumor heterogeneity may be reduced by averaging the results of replicate biopsies from multiple tumor sites whereas technical difficulties may be understood by averaging the results of replicate biopsies from the same tumor site.
In conclusion, although dasatinib did not show clinical activity in an unselected group of patients with heavily-treated MBC, this study demonstrates that multiple research biopsies with real-time pharmacodynamic tissue biomarker analysis can be conducted in the context of a phase II trial and provides a design framework that may serve as a starting point for future studies of novel targeted agents. 
